Naile eriş güdül

Dr. Naile eriş güdül

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2025 in Clinical Cardiology
Verified
Journal Article
Open access
IEIlke Erbay
Ilke Erbay
NGNaile Eris Gudul
Naile Eris Gudul
ASAhmet Furkan Süner
Ahmet Furkan Süner
PAPelin Aladag
Pelin Aladag
UKUmit Karacar
Umit Karacar
AAAhmet Avci
Ahmet Avci
Background: Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure (HF), but their effect on sleep quality (SQ) and patient‐centered outcomes remains unclear.Objective: This study aims to evaluate the impact of SGLT2 inhibitor use on SQ, anxiety, and quality of life in patients with HF.Methods: This longitudinal observational study included 95 HF patients grouped by SGLT2 inhibitor use. A total of 79 patients (SGLT2 inhibitor group: 33; non‐SGLT2 inhibitor group: 46) completed a 6‐month follow‐up. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), anxiety with the Beck Anxiety Inventory (BAI), and quality of life with the Short Form‐36 (SF‐36). Subgroup analyses were conducted based on left ventricular ejection fraction (LVEF), and logistic regression was used to identify predictors of PSQI improvement.Results: At baseline, PSQI scores were slightly better in the SGLT2 inhibitor group (p = 0.036), while BAI and SF‐36 scores were similar. At follow‐up, the SGLT2 inhibitor group showed significant improvements in PSQI (p < 0.001) and BAI (p = 0.002), whereas no significant changes were observed in the non‐SGLT2 inhibitor group for either PSQI (p = 0.698) or BAI (p = 0.373). PSQI improvement was observed in SGLT2 users regardless of LVEF. In multivariate analysis, SGLT2 inhibitor use was an independent predictor of PSQI improvement (adjusted OR: 4.255; p = 0.010).Conclusion: SGLT2 inhibitor use was associated with improved SQ and reduced anxiety in patients with HF, suggesting symptom‐related benefits beyond cardiovascular effects.

1 February 2012 in Clinical & Investigative Medicine
Verified
Journal Article
Open access
PDF file
TKTurgut Karabag
Turgut Karabag
SDSait M. Dogan
Sait M. Dogan
MAMustafa Aydin
Mustafa Aydin
MSMuhammet R. Sayin
Muhammet R. Sayin
CBCagatay Buyukuysal
Cagatay Buyukuysal
ADAbdullah Orhan Orhan Demirtas
Abdullah Orhan Orhan Demirtas
Purpose: The aim of this study is to investigate whether P wave dispersion (PWD), measured before, during and after fibrinolytic therapy (FT,) is able to predict successful reperfusion and infarct related artery (IRA) patency in patients with acute anterior MI who received FT. Methods: Sixty-eight patients who presented with acute anterior MI were enrolled in the study. An electrocardiogram was performed before and at 30, 60, 90 and 120 minutes after the start of FT. PWD was defined as the difference between maximum and minimum P wave duration on standard 12-lead surface electrocardiogram. A multivariate logistic regression model was used to assess whether PWD was predictor of IRA patency and ST-segment resolution (STR) on electrocardiogram. Results: PWD120 was significantly lower in patients with STR on electrocardiogram (38 patients) compared with those without STR (30 patients) (44.8±11.5 vs. 52.9±10.3 ms; p < 0.001). PWD120 was found to be significantly lower in patients with patent IRA (31 patients) compared to those with occluded IRA (37 patients) (42.3±9.7 vs. 53.5±10.6 ms; p < 0.001). Logistic regression analysis revealed that PWD120 significantly predicted STR and IRA patency. A ≥51.6 ms PWD120 can predict an occluded IRA with a 87% sensitivity, ≥51 ms PWD120 can predict no reperfusion with a 74% sensitivity. Conclusion: PWD values, which were higher than 51 ms and 51.6 ms in patients who received fibrinolytic therapy, can serve as a marker of failed reperfusion and occluded IRA. PWD values, in combination with other reperfusion parameters, can contribute to the identification of rescue PCI candidates.

9 July 2021 in Biomarkers in Medicine
Verified
Journal Article
Closed access
MSMustafa U Somuncu
Mustafa U Somuncu
AAAhmet Avci
Ahmet Avci
BKBelma Kalaycı
Belma Kalaycı
NGNaile E Gudul
Naile E Gudul
FTFatih P Tatar
Fatih P Tatar
FAFerit Akgul
Ferit Akgul
Aim: Although there are short- and long-term prognostic studies in patients with myocardial infarction (MI), the data that can be used to predict the clinical outcome following discharge is limited...

26 October 2024 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
UKUğur Köktürk
Uğur Köktürk
NGNaile Eriş Güdül
Naile Eriş Güdül
IEIlke Erbay
Ilke Erbay
PDPelin Ertop Doğan
Pelin Ertop Doğan
EHEmel Hazinedar
Emel Hazinedar
AAAhmet Avcı
Ahmet Avcı

31 August 2025 in Medical Journal of Western Black Sea
Verified
Journal Article
Closed access
IEİlke Erbay
İlke Erbay
NGNaile Eriş Güdül
Naile Eriş Güdül
PAPelin Aladag
Pelin Aladag
GCGüray Ceylan
Güray Ceylan
SASelim Aydemir
Selim Aydemir
AAAhmet Avci
Ahmet Avci
Aim: Inflammatory bowel disease (IBD) is a chronic disease with systemic implications, including cardiovascular effects. The aim of this study was to investigate the impact of IBD on right ventricular (RV) function and pulmonary hemodynamics, focusing on the relationship between pulmonary pulse transit time (pPTT) and other echocardiographic markers. Material and Methods: Fifty IBD patients and 50 matched healthy controls underwent echocardiographic evaluation to assess RV function, including parameters such as RV myocardial performance index (RVMPI), RV ejection fraction (RV EF) and tricuspid annular plane systolic excursion (TAPSE). Pulmonary hemodynamics were assessed by pPTT and pulmonary arterial stiffness (PAS). Statistical analyses explored the associations between IBD and these echocardiographic parameters. Results: No differences in systolic pulmonary artery pressure (sPAP) or TAPSE were observed between the groups. PAS was increased and pPTT was shortened in IBD patients compared to controls. pPTT correlated with PAS, IBD duration, RV EF, RV fractional area change (RVFAC), TAPSE, tricuspid S', RVMPI and C-reactive protein (CRP). pPTT was an independent predictor of PAS (p < 0.001). Conclusion: IBD patients show impaired RV function and increased pulmonary stiffness. pPTT may serve as a practical marker for early detection of pulmonary vascular changes in IBD, replacing PAS for hemodynamic assessment.

1 January 2025 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
IEİlKe Erbay
İlKe Erbay
RARabia Hande Avcı
Rabia Hande Avcı
NGNaile Eriş Güdül
Naile Eriş Güdül
MAMurat Altuntaş
Murat Altuntaş
ASAhmet Furkan Süner
Ahmet Furkan Süner
AAAhmet Avci
Ahmet Avci
Background: Obstructive sleep apnea (OSA) is associated with increased cardiovascular risk, particularly through right ventricular (RV) dysfunction. Cancer antigen 125 (CA125), a biomarker traditionally used in ovarian cancer, has shown potential as an indicator of RV dysfunction. This study aims to compare CA125 levels between OSA patients and controls and to evaluate its association with disease severity and subclinical RV dysfunction. Methods: This cross-sectional study included sixty OSA patients, divided into severe (apnea-hypopnea index [AHI] ≥ 30) and non-severe groups, and sixty age- and sex-matched controls. Cancer antigen 125 levels were assessed together with echocardiographic markers. Regression analysis identified predictors of severe OSA, and receiver operating characteristic (ROC) analysis assessed the diagnostic performance of CA125. Results: Cancer antigen 125 levels were significantly elevated in severe OSA patients compared to non-severe and control groups (median 34.3 vs. 12.9 vs. 10.3 U/mL, P < .001). Cancer antigen 125 correlated with RV fractional area change (RV-FAC) (r = −0.496, P < .001), tricuspid annular plane systolic excursion (TAPSE) (r = −0.285, P = .027), and AHI (r = 0.581, P < .001). Regression analysis identified CA125 (odds ratio [OR] = 1.259, 95% con-fidence interval [CI]: 1.102-1.438, P = .001) and TAPSE (OR= 0.425, 95% CI: 0.217-0.834, P = .013) as independent predictors of severe OSA. ROC analysis showed that CA125 could effectively predict RV dysfunction (area under the curve [AUC] = 0.857) and severe OSA (AUC = 0.804). Conclusion: Elevated CA125 levels are associated with increased disease severity and subclinical RV dysfunction in OSA, suggesting its potential as a biomarker for early cardiac involvement.